ERBB2 and breast cancer: In conclusion, we showed that Oncotype DX significantly increased physicians’ confidence in adjuvant chemotherapy recommendations and agreement among oncologists in providing adiuvant treatment recommendations for patients with ER+/HER2− early breast cancer.